ERBB2 and breast cancer: In this context, the present study represents, to our knowledge, the largest study assessing the effectiveness of the APT regimen in a real-world patient cohort, and our results generally confirm that the use of the APT regimen in patients with Stage I HER2 + BC is associated with a good prognosis.